NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) (NASDAQ:OREX) securities between March 3, 2015 and March 5, 2015.
Click here to learn about the case: http://docs.wongesq.com/OREX-Info-Request-Form-675. There is no cost or obligation to you.
The complaint alleges that as part of the FDA’s post-marketing approval process for its drug Contrave, Orexigen was required to conduct a “new … study to evaluate the effects of long-term treatment with Contrave on the incidence of [major adverse cardiac events] in overweight and obese subjects with [cardiovascular] disease or multiple [cardiovascular] risk factors.” The complaint alleges that on March 3, 2015, Orexigen disclosed detailed interim results of its ongoing study despite the fact that the Company had been previously admonished by the FDA for inappropriately releasing interim study data. On March 5, 2015, a report published by Forbes quoted a purported FDA official as saying the interim data from the study was probably “unreliable” and “misleading” and suggesting that Orexigen could “face fines, civil penalties, or even the withdrawal of Contrave from the market.”
If you suffered a loss in Orexigen you have until May 11, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/OREX-Info-Request-Form-675.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.